-
Mashup Score: 9
Phase 1–2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy. In this phase 3 trial,…
Source: www.nejm.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 9
Phase 1–2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy. In this phase 3 trial,…
Source: www.nejm.orgCategories: General Medicine News, Oncologists2Tweet-
So proud of our work @NKI_nl @MelanomaAus for #Nadina trial. #neoadjuvant #checkpoint #immunotherapy 68% decrease risk of progression/recurrence & death vs adjuvant anti-pd1. Multidisciplinary teamwork-great for patients with macroscopic stage 3 melanoma. https://t.co/5jatsFsxJ0 https://t.co/AkznUCZ3Yr
-
-
Mashup Score: 9
Phase 1–2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy. In this phase 3 trial,…
Source: www.nejm.orgCategories: General Medicine News, Oncologists2Tweet-
So proud of our work @NKI_nl @MelanomaAus for #Nadina trial. #neoadjuvant #checkpoint #immunotherapy 68% decrease risk of progression/recurrence & death vs adjuvant anti-pd1. Multidisciplinary teamwork-great for patients with macroscopic stage 3 melanoma. https://t.co/5jatsFsxJ0 https://t.co/AkznUCZ3Yr
-
-
Mashup Score: 9
Phase 1–2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy. In this phase 3 trial,…
Source: www.nejm.orgCategories: General Medicine News, Oncologists2Tweet-
So proud of our work @NKI_nl @MelanomaAus for #Nadina trial. #neoadjuvant #checkpoint #immunotherapy 68% decrease risk of progression/recurrence & death vs adjuvant anti-pd1. Multidisciplinary teamwork-great for patients with macroscopic stage 3 melanoma. https://t.co/5jatsFsxJ0 https://t.co/AkznUCZ3Yr
-
-
Mashup Score: 9
Phase 1–2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy. In this phase 3 trial,…
Source: www.nejm.orgCategories: General Medicine News, Oncologists2Tweet-
So proud of our work @NKI_nl @MelanomaAus for #Nadina trial. #neoadjuvant #checkpoint #immunotherapy 68% decrease risk of progression/recurrence & death vs adjuvant anti-pd1. Multidisciplinary teamwork-great for patients with macroscopic stage 3 melanoma. https://t.co/5jatsFsxJ0 https://t.co/AkznUCZ3Yr
-
-
Mashup Score: 8Home - ClinicalTrials.gov - 16 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine. IMPORTANT: Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Search for
Source: clinicaltrials.govCategories: General Medicine News, Oncologists2Tweet-
RT @jillfeldman4: The most experienced patients & advocates struggle to search for #clinicaltrial, even on https://t.co/ZNn0IP9nxh. A user-…
-
-
Mashup Score: 11Login - 21 day(s) ago
3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462 Phone: 215-690-0300 Fax: 215-690-0280 Copyright © National Comprehensive Cancer Network, All Rights Reserved. No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.See Legal Notices Section…
Source: www.nccn.orgCategories: General Medicine News, Oncologists2Tweet-
RT @RielyMD: Updated NCCN guidelines for treatment of patients with thymoma and thymic carcinoma were released. https://t.co/A5BHTDMe3l For…
-
-
Mashup Score: 1Home - XXV Congresso Nazionale AIOM - 2023 - 23 day(s) ago
XXV Congresso Nazionale AIOM – 10-11-12 novembre2023
Source: congresso.aiom.itCategories: General Medicine News, Oncologists2Tweet-
RT @AIOMtweet: #AIOM23 is coming soon… https://t.co/o2HGN8HSZe https://t.co/kergvdqxEW
-
-
Mashup Score: 2Connecticut Governor and Comptroller urge Prospect Medical Holdings and YNHH to close $435 million acquisition deal - 26 day(s) ago
Officials argue that the deal’s collapse negatively impacts local communities, while two hospital systems battle over the deal in courts.
Source: yaledailynews.comCategories: General Medicine News, Oncologists2Tweet-
Connecticut Governor and Comptroller urge Prospect Medical Holdings and YNHH to close $435 million acquisition deal Officials argue that the deal’s collapse negatively impacts local communities, while two hospital systems battle over the deal in courts. https://t.co/alp8mMlh6l
-
-
Mashup Score: 31Lung Young Connection - 28 day(s) ago
Dra. Laura Mezquita y Dra. Maria Saigí Dr. Alex Martínez Hospital Vall d’Hebrón Unidad de Tumores Torácicos, Servicio de Oncología Médica; Laboratorio de Genómica Traslacional Unidad de Tumores Torácicos, Servicio de Oncología Médica; Laboratorio de Genómica Traslacional Unidad de Tumores Torácicos y Cutáneos, Servicio de Oncología Médica Unidad de Tumores Torácicos; Unidad de Ensayos Clínicos Fase 1, Servicio de Oncología Médica Dr. Alex Martínez Hospital Vall d’Hebrón Unidad de Tumores Torácicos,
Source: www.lungyoungconnection.comCategories: General Medicine News, Oncologists2Tweet-
📍Residentes & fellows oncología, y estudiantes #Medicina os esperamos esta tarde @hospitalclinic Empezamos 2a Ed. #LungYoungConnection 👩🏻⚕️🫁 5 Hospitales #Barcelona 1a sesión: #MedicinaPrecision #CancerPulmon 🧬🔬🩺 #ClinicCancerCenter 👇 info: https://t.co/moJvETUPo6 https://t.co/16GEGrCx6x
-
So proud of our work @NKI_nl @MelanomaAus for #Nadina trial. #neoadjuvant #checkpoint #immunotherapy 68% decrease risk of progression/recurrence & death vs adjuvant anti-pd1. Multidisciplinary teamwork-great for patients with macroscopic stage 3 melanoma. https://t.co/5jatsFsxJ0 https://t.co/AkznUCZ3Yr